The European Commission said on Friday it had reached a deal with British pharmaceutical firm AstraZeneca for the purchase of at least 300 million doses of its potential COVID-19 vaccine.
AstraZeneca Mexico's head said that Phase III trials were expected to conclude by November or December
The US government previously gave Moderna around $1 billion to fund its research efforts, bringing total US funding to around $2.5 billion
Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June. The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing. Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added. The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said. Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.
AstraZeneca signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its Covid-19 vaccine candidate in mainland China
Moves by the US and UK to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements
The company reiterated that it was on track with late-stage trials for its coronavirus vaccine, which could be rolled out by the year-end
The drug Breztri Aerosphere is being approved as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death globally
The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said
Serum Institute CEO didn't specify quantity of doses to be kept for community grappling with shrinking population
Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries
Serum Institute of India, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready.
Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222
Study shows the vaccine is safe, but it is still too soon to know if it can stop people from being infected
The preliminary results of the phase 1-2 trial, published in The Lancet journal, involved 1,107 healthy adults, and found that the vaccine induced an immune response both via antibodies and T-cells
Deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford
Most players that Business Standard spoke to said they would be concentrating on their own vaccine candidates or the current tie-ups that they have
AstraZeneca's experimental vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's chief scientist said in June
Called the Dare 19 trial, it is one of the several global research efforts by the British company to find a solution to treat Covid-19
On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.